Pharmacophore modeling and in silico toxicity assessment of potential anticancer agents from African medicinal plants

Drug Design, Development and Therapy

Volumn 10, Issue , 2016, Pages 2137-2154

  Ntie Kang, Fidele ^a,b   Simoben, Conrad Veranso ^a,b   Karaman, Berin ^a   Ngwa, Valery Fuh ^c   Judson, Philip Neville ^d   Sippl, Wolfgang ^a   Mbaze, Luc Meva’A ^e  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF BUEA   (Cameroon)

^c HASSELT UNIVERSITY   (Belgium)

^d Chemical Bioactivity Information Centre   (United Kingdom)

^e UNIVERSITY OF DOUALA   (Cameroon)

Author keywords

Anticancer; Medicinal plants; Natural products; Pharmacophore; Toxicity; Virtual screening

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE; GLYCOGEN SYNTHASE KINASE; INDOLEAMINE 2,3 DIOXYGENASE; PROTEIN FARNESYLTRANSFERASE; PROTEIN KINASE; PROTEIN KINASE B BETA; PROTEIN TYROSINE KINASE; PROTEIN KINASE B;

AFRICAN MEDICINE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; GUNER HENRY SCORE; HYDROPHOBICITY; MEDICINAL PLANT; MOLECULAR MODEL; PHARMACOPHORE; PHYSICAL CHEMISTRY; PRINCIPAL COMPONENT ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; SCREENING; STRUCTURE ANALYSIS; TOXICITY; CHEMISTRY; COMPUTER SIMULATION; DRUG DESIGN; FACTUAL DATABASE; HUMAN; METABOLISM;

ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; DATABASES, FACTUAL; DRUG DESIGN; HUMANS; MODELS, MOLECULAR; PLANTS, MEDICINAL; PROTO-ONCOGENE PROTEINS C-AKT;

EID: 84979073407     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S108118     Document Type: Article

References (115)

1. Gibbs JB. Mechanism-based target identification and drug discovery in cancer research. Science. 2000;287(5460):1969–1973.
2. WHO Media Centre [webpage on the Internet]. Fast sheet No 297; 2013. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/index.html. Accessed February 4, 2014.
3. [webpage on the Internet]. Globocan Fast Stats; 2008. Available from: http://www.iarc.fr/en/media-centre/iarcnews/2010/globocan2008.php. Accessed August 4, 2013.
4. Newman DJ, Cragg GM, Snader KM. The influence of natural products upon drug discovery. Nat Prod Rep. 2000;17(3):215–234.
5. Hostettmann K, Terreaux C. Search for new lead compounds from higher plants. Chimia. 2000;54(11):652–657.
6. Saklani A, Kutty SK. Plant-derived compounds in clinical trials. Drug Discov Today. 2008;13(3):161–171.
7. Salim AA, Chin YW, Kinghorn AD. Drug discovery from plants. In: Ramawat KG, Merillon JM, editors. Bioactive Molecules and Medicinal Plants. Heidelberg: Springer; 2008:1–24.
8. Kinghorn AD, Pan L, Fletcher JN, Chai H. The relevance of higher plants in lead compound discovery programs. J Nat Prod. 2011;74(6): 1539–1555.
9. Grothaus PG, Cragg GM, Newman DJ. Plant natural products in anticancer drug discovery. Curr Org Chem. 2010;14(16):1781–1791.
10. Ashutosh K. Medicinal Chemistry. New Delhi, India: New Age International Ltd.; 2007:794.
11. Desai AG, Qazi GN, Ganju RK, et al. Medicinal plants and cancer chemoprevention. Curr Drug Metab. 2008;9(7):581–591.
12. Heinrich M, Bremner P. Ethnobotany and ethnopharmacy – their role for anti-cancer drug development. Curr Drug Targets. 2006;7(3): 239–245.
13. Cragg GM, Newman DJ. Nature: a vital source of leads for anticancer drug development. Phytochem Rev. 2009;8(2):313–331.
14. Hollósy F, Kéri G. Plant-derived protein tyrosine kinase inhibitors as anticancer agents. Curr Med Chem Anticancer Agents. 2004;4(2): 173–197.
15. Clardy J, Walsh C. Lessons from natural molecules. Nature. 2004; 432(7019):829–837.
16. Reddy L, Odhav B, Bhoola KD. Natural products for cancer prevention: a global perspective. Pharmacol Ther. 2003;99(1):1–13.
17. Lucas DM, Still PC, Pérez LB, Grever MR, Kinghorn AD. Potential of plant-derived natural products in the treatment of leukemia and lymphoma. Curr Drug Targets. 2010;11(7):812–822.
18. Wang HK, Lee KH. Plant-derived anticancer agents and their analogs currently in clinical use or in clinical trials. Bot Bull Acad Sinica. 1997; 38:225–235.
19. Pan L, Chai H, Kinghorn AD. The continuing search for antitumor agents from higher plants. Phytochem Lett. 2010;3(1):1–8.
20. Cragg GM, Newman DJ. Plants as a source of anti-cancer agents. J Ethnopharmacol. 2005;100(1):72–79.
21. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005;78(5):431–441.
22. Srivastava V, Negi AS, Kumar JK, Gupta MM, Khanuja SP. Plant-based anticancer molecules: a chemical and biological profile of some important leads. Bioorg Med Chem. 2005;13(21):5892–5908.
23. Cragg GM, Grothaus PG, Newman DJ. Impact of natural products on developing new anti-cancer agents. Chem Rev. 2009;109(7): 3012–3043.
24. Gurib-Fakim A. Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspects Med. 2006;27(1):1–93.
25. Nobili S, Lippi D, Witort E, et al. Natural compounds for cancer treatment and prevention. Pharmacol Res. 2009;59(6):365–378.
26. Lee KH. Anticancer drug design based on plant-derived natural products. J Biomed Sci. 1999;6(4):236–250.
27. Gordaliza M. Natural products as leads to anticancer drugs. Clin Transl Oncol. 2007;9(12):767–776.
28. Connors T. Anticancer drug development: the way forward. Oncologist. 1996;1(3):180–181.
29. Fadeyi SA, Fadeyi OO, Adejumo AA, Okoro C, Myles EL. In vitro anticancer screening of 24 locally used Nigerian medicinal plants. BMC Complement Altern Med. 2013;13(1):79.
30. Ntie-Kang F, Zofou D, Babiaka SB, et al. AfroDb: a select highly potent and diverse natural product library from African medicinal plants. PLoS One. 2013;8(10):e78085.
31. Sawadogo WR, Schumacher M, Teiten MH, Dicato M, Diederich M. Traditional West African pharmacopeia, plants and derived compounds for cancer therapy. Biochem Pharmacol. 2012;84(10):1225–1240.
32. Ntie-Kang F, Nwodo JN, Ibezim A, et al. Molecular modeling of potential anticancer agents from African medicinal plants. J Chem Inf Model. 2014;54(9):2433–2450.
33. Ntie-Kang F, Lifongo LL, Judson PN, Sippl W, Efange SMN. How “drug-like” are naturally occurring anti-cancer compounds? J Mol Model. 2014;20(1):1–13.
34. Mangal M, Sagar P, Singh H, Raghava GP, Agarwal SM. NPACT: naturally occurring plant-based anti-cancer compound-activity-target database. Nucleic Acids Res. 2013;41(D1):D1124–D1129.
35. Cragg GM, Newman DJ. Plants as a source of anti-cancer and anti-HIV agents. Ann Appl Biol. 2003;143(2):127–133.
36. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012;75(3):311–335.
37. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007;70(3):461–477.
38. Hostettmann K, Marston A, Ndjoko K, Wolfender JL. The potential of African plants as a source of drugs. Curr Org Chem. 2000;4(10): 973–1010.
39. Sandberg F, Perera-Ivarsson P, El-Seedi HR. A Swedish collection of medicinal plants from Cameroon. J Ethnopharmacol. 2005;102(3): 336–343.
40. El-Seedi HR, Burman R, Mansour A, et al. The traditional medical uses and cytotoxic activities of sixty-one Egyptian plants: discovery of an active cardiac glycoside from Urginea maritima. J Ethnopharmacol. 2013;145(3):746–757.
41. Efange SMN. Natural products: a continuing source of inspiration for the medicinal chemist. In: Iwu MM, Wootton JC, editors. Ethnomedicine and Drug Discovery; Advances in Phytomedicine. Vol. 1. Amsterdam, Netherlands: Elsevier Science; 2002:61–69.
42. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22(2): 151–185.
43. Klebe G. Virtual ligand screening strategies; perspective and limitations. Drug Discov Today. 2006;11(13):580–594.
44. Kubinyi H. Structure-based design of enzyme inhibitors and receptor ligands. Curr Opin Drug Discov Devel. 1998;1(1):4–15.
45. Chen H, Yao K, Nadas J, et al. Prediction of molecular targets of cancer preventing flavonoid compounds using computational methods. PLoS One. 2012;7(5):e38261.
46. Paul J, Gnanam R, Jayadeepa RM, Arul L. Anti cancer activity on Graviola, an exciting medicinal plant extract vs various cancer cell lines and a detailed computational study on its potent anti-cancerous leads. Curr Top Med Chem. 2013;13(14):1666–1673.
47. Vyas VK, Ghate M, Goel A. Pharmacophore modeling, virtual screening, docking and in silico ADMET analysis of protein Kinase B (PKB β) inhibitors. J Mol Graph Model. 2013;42:17–25.
48. Fan Y, Shi LM, Kohn KW, Pommier Y, Weinstein JN. Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies. J Med Chem. 2001;44(20):3254–3263.
49. Zhou H, Wu S, Zhai S, et al. Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem. 2008;51(5):1242–1251.
50. Chiang YK, Kuo CC, Wu YS, et al. Generation of ligand-based pharmacophore model and virtual screening for identification of novel tubulin inhibitors with potent anticancer activity. J Med Chem. 2009;52(14):4221–4233.
51. Kim DY, Kim KH, Kim ND, et al. Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin. J Med Chem. 2006;49(19):5664–5670.
52. Ojima I, Chakravarty S, Inoue T, et al. A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Natl Acad Sci U S A. 1999;96(8):4256–4261.
53. Pérez-Sacau E, Díaz-Penãte RG, Estévez-Braun A, et al. Synthesis and pharmacophore modeling of naphthoquinone derivatives with cytotoxic activity in human promyelocytic leukemia HL-60 cell line. J Med Chem. 2007;50(4):696–706.
54. Ntie-Kang F, Mbah JA, Mbaze LM, et al. CamMedNP: building the Cameroonian 3D structural natural products database for virtual screening. BMC Complement Altern Med. 2013;13:88.
55. Ntie-Kang F, Onguéné PA, Scharfe M, et al. ConMedNP: a natural product library from medicinal plants in Central Africa. RSC Adv. 2014; 4:409–419.
56. Ntie-Kang F, Amoa Onguéné P, Fotso GW, et al. Virtualizing the p-ANAPL library: a step towards drug discovery from African medicinal plants. PLoS One. 2014;9(3):e90655.
57. Ntie-Kang F, Lifongo LL, Mbah JA, et al. In silico drug metabolism and pharmacokinetic profiles of natural products from medicinal plants in the Congo Basin. In Silico Pharmacol. 2013;1:12.
58. Ntie-Kang F, Mbah JA, Lifongo LL, et al. Assessing the pharmacokinetic profile of the CamMedNP natural products database: an in silico approach. Org Med Chem Lett. 2013;3(1):10.
59. Onguéné PA, Ntie-Kang F, Mbah JA, et al. The potential of anti-malarial compounds derived from African medicinal plants, part III: an in silico evaluation of drug metabolism and pharmacokinetics profiling. Org Med Chem Lett. 2014;4(1):6.
60. Wolber G, Langer T. LigandScout: 3D-pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. 2005;45(1):160–169.
61. Berman HM, Westbrook J, Feng Z, et al. The protein data bank. Nucleic Acids Res. 2000;28(1):235–242.
62. Chemical Computing Group Inc. Molecular Operating Environment, Version 2010. Montreal: Chemical Computing Group Inc; 2010.
63. Halgren TA. Merck molecular forcefield. J Comput Chem. 1996;17: 490–441.
64. Schrödinger LLC. LigPrep Software, Version 2.5. New York: Schrödinger LLC; 2011.
65. Mysinger MM, Carchia M, Irwin JJ, Shoichet BK. Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem. 2012;55(14):6582–6594.
66. Güner OF, Henry DR. Pharmacophore perception, development, and use in drug design. In: Güner OF, editor. Metric for Analyzing Hit Lists and Pharmacophores; IUL Biotechnology Series. La Jolla, CA: International University Line; 2000:191–212.
67. Güner OF, Waldman M, Hoffmann RD, Kim JH. Pharmacophore perception, development, and use in drug design. In: Güner OF, editor. Strategies for Database Mining and Pharmacophore Development; IUL Biotechnology Series, 1st Edition. La Jolla, CA: International University Line; 2000:213–236.
68. Langer T, Hoffmann RD. Pharmacophores and Pharmacophore Searches. Weinheim, Germany: WILEY-VCH; 2006:338–340.
69. Lhasa Limited [webpage on the Internet]. Derek Nexus. Available from: http://www.lhasalimited.org/products/derek-nexus.htm. Accessed May 19, 2015.
70. Wold S, Esbensen K, Geladi P. Principal component analysis. Chemometr Intell Lab Syst. 1987;2:37–52.
71. Lewell XQ, Judd DB, Watson SP, Hann MM. RECAP – retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comput Sci. 1998;38(3):511–522.
72. ChemAxon [webpage on the Internet]. JChem Software, Version 5.11.3; 2012. Available from: https://www.chemaxon.com/jchem/doc/user/LibMCS.html. Accessed May 19, 2015.
73. Nagar B, Bornmann WG, Pellicena P, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. 2002;62(15):4236–4243.
74. Wisniewski D, Lambek CL, Liu C, et al. Characterization of potent inhibitors of the Bcr-Abl and the c-Kit receptor tyrosine kinases. Cancer Res. 2002;62(15):4244–4255.
75. Zimmermann J, Buchdunger E, Mett H, Meyer T, Lydon NB. Potent and selective inhibitors of the Abl-kinase: phenylaminopyrimidine (Pap) derivatives. Bioorg Med Chem Lett. 1997;329(7):187–192.
76. Kraker AJ, Hartl BG, Amar AM, Barvian MR, Showalter HD, Moore CW. Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000;60(7):885–898.
77. McHardy T, Caldwell JJ, Cheung KM, et al. Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt). J Med Chem. 2010; 53(5):2239–2249.
78. Caldwell JJ, Davies TG, Donald A, et al. Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. J Med Chem. 2008;51(7):2147–2157.
79. Donald A, McHardy T, Rowlands MG, et al. Rapid evolution of 6-phenylpurine inhibitors of protein kinase B through structure-based design. J Med Chem. 2007;50(10):2289–2292.
80. Wang S, Griffiths G, Midgley CA, et al. Discovery and characterization of 2-anilino-4-(thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. Chem Biol. 2010;17(10):1111–1121.
81. Hast MA, Fletcher S, Cummings CG, et al. Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase. Chem Biol. 2009;16(2):181–192.
82. Battistutta R, Cozza G, Pierre F, et al. Unprecedented selectivity and structural determinants of a new class of protein kinase ck2 inhibitors in clinical trials for the treatment of cancer. Biochemistry. 2011; 50(39):8478–8488.
83. Pierre F, Stefan E, Nédellec AS, et al. 7-(4H-1,2,4-triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett. 2011; 21(22):6687–6692.
84. Hou Z, Nakanishi I, Kinoshita T, et al. Structure-based design of novel potent protein kinase CK2 (CK2) inhibitors with phenyl-azole scaffolds. J Med Chem. 2012;55(6):2899–2903.
85. Pierre F, Regan CF, Chevrel MC, et al. Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells. Bioorg Med Chem Lett. 2012;22(9):3327–3331.
86. Berg S, Bergh M, Hellberg S, et al. Discovery of novel potent and highly selective glycogen synthase kinase-3β (GSK3β) inhibitors for Alzheimer’s disease: design, synthesis, and characterization of pyrazines. J Med Chem. 2012;55(21):9107–9119.
87. Coghlan MP, Culbert AA, Cross DA, et al. Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol. 2000;7(10):793–803.
88. Good JA, Wang F, Rath O, et al. Optimized S-trityl-L-cysteine-based inhibitors of kinesin spindle protein with potent in vivo antitumor activity in lung cancer xenograft models. J Med Chem. 2013;56(5):1878–1893.
89. Tojo S, Kohno T, Tanaka T, et al. Crystal structures and structure-activity relationships of imidazothiazole derivatives as IDO1 inhibitors. ACS Med Chem Lett. 2014;5(10):1119–1123.
90. Fawcett T. An introduction to ROC analysis. Pattern Recognit Lett. 2006;27(8):861–874.
91. Yang JM, Shen TW. A Pharmacophore-based evolutionary approach for screening selective estrogen receptor modulators. Proteins. 2005; 59(2):205–220.
92. Muegge I. Selection criteria for drug-like compounds. Med Res Rev. 2003;23(3):302–321.
93. Ntie-Kang F, Kannan S, Wichapong K, Owono Owono LC, Sippl W, Megnassan E. Binding of pyrazole-based inhibitors to Mycobacterium tuberculosis pantothenate synthetase: docking and MM-GB(PB)SA analysis. Mol Biosyst. 2014;10(2):223–239.
94. Liao HS, Liu HL, Chen WH, Ho Y. Structure-based pharmacophore modeling and virtual screening to identify novel inhibitors for anthrax lethal factor. Med Chem Res. 2014;23(8):3725–3732.
95. Koide Y, Uemoto K, Hasegawa T, et al. Pharmacophore-based design of sphingosine 1-phosphate-3 receptor antagonists that include a 3,4-dialkoxybenzophenone scaffold. J Med Chem. 2007;50(3):442–454.
96. Lu SH, Wu JW, Liu HL, et al. The discovery of potential acetylcholinesterase inhibitors: a combination of pharmacophore modeling, virtual screening, and molecular docking studies. J Biomed Sci. 2011;18:8.
97. Seal A, Yogeeswari P, Sriram D; OSDD Consortium, Wild DJ. Enhanced ranking of PknB inhibitors using data fusion methods. J Cheminform. 2013; 5(1):2.
98. Kalva S, Azhagiya Singam ER, Rajapandian V, Saleena LM, Subramanian V. Discovery of potent inhibitor for matrix metalloproteinase-9 by pharmacophore based modeling and dynamics simulation studies. J Mol Graph Model. 2014;49:25–37.
99. Sanderson DM, Earnshaw CG. Computer prediction of possible toxic action from chemical structure; the DEREK system. Hum Exp Toxicol. 1991;10(4):261–273.
100. Greene N, Judson PN, Langowski JJ, Marchant CA. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR QSAR Environ Res. 1999;10(2–3):299–314.
101. Marchant CA, Briggs KA, Long A. In silico tools for sharing data and knowledge on toxicity and metabolism: Derek for Windows, Meteor, and Vitic. Toxicol Mech Methods. 2008;18(2–3):177–187.
102. Ridings JE, Barratt MD, Cary R, et al. Computer prediction of possible toxic action from chemical structure: an update on the DEREK system. Toxicology. 1996;106(13):267–279.
103. Greene N. Computer software for risk assessment. J Chem Inf Comput Sci. 1997;37(1):148–150.
104. Marchant CA. Computational toxicology: a tool for all industries. Wiley Interdiscip Rev Comput Mol Sci. 2012;2(3):424–434.
105. Sherhod R, Gillet VJ, Judson PN, Vessey JD. Automating knowledge discovery for toxicity prediction using jumping emerging pattern mining. J Chem Inf Model. 2012;52(11):3074–3087.
106. Happi EN, Waffo AF, Wansi JD, Ngadjui BT, Sewald N. O-prenylated acridone alkaloids from the stems of Balsamocitrus paniculata (Rutaceae). Planta Med. 2011;77(9):934–938.
107. Tsassi VB, Hussain H, Meffo BY, et al. Antimicrobial coumarins from the stem bark of Afraegle paniculata. Nat Prod Commun. 2010; 5(4):559–561.
108. Wall ME, Wani MC, Hughes TJ, Taylor H. Plant antimutagenic agents, 1. General bioassay and isolation procedure. J Nat Prod. 1988; 51(5):866–873.
109. Zhang Y, Cao Y, Zhan Y, Duan H, He L. Furanocoumarins-imperatorin inhibits myocardial hypertrophy both in vitro and in vivo. Fitoterapia. 2010;81(8):1188–1195.
110. Khalid H, Abdalla WE, Abdelgadir H, Opatz T, Efferth T. Gems from traditional North-African medicine: medicinal and aromatic plants from Sudan. Nat Prod Bioprospect. 2012;2(3):92–103.
111. National Toxicology Program (NTP). Toxicology and carcinogenesis studies of 8-methoxypsoralen (CAS No 298-81-7) in F344/N rats (gavage studies). National Toxicology Program Report, Additional Content: TR-359; Chapel Hill, USA; 1989.
112. Dall’Acqua F, Terbojevich M, Marciani S, Vedaldi D, Recher M. Investigation of the dark interaction between furocoumarins and DNA. Chem Biol Interact. 1978;21(1):103–115.
113. Quinto I, Averbeck D, Moustacchi E, Hrisoho Z, Moron J. Frameshift mutagenicity in Salmonella typhimurium of furocoumarins in the dark. Mutat Res. 1984;136(1):49–54.
114. Ferguson LR, Denny WA. The genetic toxicology of acridines. Mutat Res. 1991;258(2):123–160.
115. Albertini S, Bös M, Gocke E, Kirchner S, Muster W, Wichmann J. Suppression of mutagenic activity of a series of 5HT2c receptor agonists by the incorporation of a gem-dimethyl group: SAR using the Ames test and a DNA unwinding assay. Mutagenesis. 1998;13(4):397–403.